The Effect of a Thromboxane Synthetase Inhibitor, Sodium Ozagrel, on Pregnancy-induced Hypertension

Abstract

Synthetic selective thromboxane synthetase inhibitor, sodium ozagrel was administered intravenously to 5 pre-eclamptic pregant women at 29 - 35 weeks ges tation. Dose of ozagrel was 80 - 160 mg/day and was infused continuously for 8 - 22 days. 

Systolic and diastolic blood pressure decreased gradually and became stable in all patients after administration of ozagrel. Clinical signs improved and protein uria decreased. In one patient, blood pressure became stable at first but then became uncontrollable. Caesarean section was performed in 2 patients because of fetal dis tress and severe hypertension. All neonates were well-developed without any compli cations. 

Thromboxane B, to 6-keto-PGF, ratio and 2,3-dinor-thromboxane B, values decreased after administration of sodium ozagrel. 

Sodium ozagrel seems likely to be useful and effective for stabilization of blood pressure and prevention of exacerbation. The results of this initial clinical study are very encouraging with respect to the treatment and prevention of preg nancy-induced hypertension. (Thai J obstet Gynaecol 1991; 3:39-44.)